Skip to content Skip to footer

Pharmacy Outlook Italia 2026

White Paper · Mikaline Research 2026

Where will your pharmacy be in 2045?

The Italian pharmacy is at a historic crossroads. Between consolidation, the entry of capital and demographic decline, value is concentrating in the most organized structures. Pharmacy Outlook Italia 2026: the data, the scenarios and the 10 priorities to avoid falling behind.

INDEPENDENT RESEARCH · PDF · FREE · NO SPAM

Download the White Paper

Mikaline Research study · PDF · free

Te lo inviamo su WhatsApp. Appena compili, ricevi il White Paper direttamente sul tuo cellulare. Inserisci un numero vero, è lì che arriva.
🇮🇹 +39

📱 Te lo inviamo subito su WhatsApp a questo numero. Solo cellulari italiani, non fissi.

Perfect! Here's the White Paper.

Il download è partito. Te lo stiamo inviando anche su WhatsApp. Se non parte, click here. We've also sent it to you by email.

The change underway

The market is growing. But the value is concentrating elsewhere.

Health demand will keep growing as the population ages. The problem is that economic value is shifting toward the larger, more organized pharmacies.

🏦

Capital enters

Dr. Max, Hippocrates, Farmagorà and the funds are acquiring the pharmacies with the best fundamentals.

📉

Demographic decline

-4/5 million inhabitants by 2050 and up to 1,600 pharmacies at risk in inland areas.

⚖️

Polarized market

33% of pharmacies generate 56% of turnover. The bottom third only 9%.

💶

The value shifts

From revenue multiples to EBITDA: 7-10x in the cities, much less where demographics decline.

The research figures

The 2025 snapshot

€27.8 bn

Value of the pharmacy market 2025 (+4% on the previous year)

20 → 25%

Share of organized pharmacies: already in 2026

23%

Of the turnover generated by just ~2,000 pharmacies (top decile)

2-4%

Share to which small independents could shrink by 2045

Source: Pharmacy Outlook Italia 2026 — Mikaline Research, on IQVIA, ISTAT data and proprietary forecasting models.

The real news

It no longer matters whether you're independent or a chain. What matters is whether you can evolve.

The research is clear: there will be extremely innovative independent pharmacies and large organizations unable to make the most of their human capital. Success doesn't depend on ownership, but on the quality of management.

The challenge is no longer just to dispense medicines: it's to build an integrated pharmacy that combines clinical skills, managerial efficiency, technology and the relationship with the patient.

“Health demand will grow. But economic value will concentrate in the most organized structures.”

White Paper Pharmacy Outlook Italia 2026

Inside the document

What's in the White Paper

A quantitative and managerial analysis of the future of the Italian pharmacy, from 2026 to 2045.

01

The 2025 market

Size, resilience, high-margin categories and the weight of e-commerce.

02

Why the chains perform

Average receipt, inventory turnover, non-pharma: the indicators compared.

03

The impact of demographics

Aging, depopulation of inland areas and pharmacies at risk.

04

The 2030-2045 scenarios

Three Mikaline projections on the competitive evolution of the sector.

05

The new economic value

From turnover to EBITDA: how the pharmacy's valuation will change.

06

Customer Experience

The patient journey and CX as a true competitive advantage.

Copertina Executive Summary Il mercato Priorità strategiche

The compass

The 10 strategic priorities

Mikaline Research's final recommendations for the pharmacy that wants to stay competitive.

1
Governing dataFrom intuitive decisions to evidence-based decisions.
2
Measuring performanceEconomic, operational and relational KPIs.
3
Investing in peopleEmployee Experience as a competitive advantage.
4
Rethinking the layoutDesigning the pharmacy around services.
5
Integrating digitalA truly omnichannel experience.
6
Developing the Customer ExperienceMeasuring it and making it part of the strategy.
7
Diversifying revenueMore weight on services and high-margin categories.
8
AggregatingEconomies of scale and negotiating power.
9
Planning the assetsSeparate operational management and real estate, when appropriate.
10
Preparing for changeSpeed of adaptation will be the no.1 competitive factor.
MR

An independent study by Mikaline Research (Milan), edited by the Mikaline Research study center. Compiled on public data, specialized databases and proprietary forecasting models. Servizi Farmacia Italia, in the person of Dr. Giuseppe Tura, contributed professional insight to the drafting of the document.

The questions we get asked

Legitimate doubts, clear answers

Is it useful even if I have a small pharmacy?

Above all. The research shows that size matters less than the ability to evolve: the document gives you the data and priorities to compete even as an independent, avoiding ending up in the bottom third of the market.

Is it a sales document?

No. It's an independent study by Mikaline Research based on IQVIA, ISTAT data and forecasting models. It sells nothing: it offers an objective picture for making better decisions.

How long is it?

It's a complete White Paper with executive summary, market analysis, 2030-2045 scenarios, the new economic valuation model, Customer Experience and 10 operational recommendations.

Why does Servizi Farmacia Italia share it?

Because SFI contributed to the research and believes in spreading a managerial culture of the pharmacy. We train owners to read these scenarios and act accordingly.

Is the data up to date?

Yes: they capture the 2025 market (€27.8 billion) and project the evolution through to 2045, with the consolidation and demographic dynamics already underway.

Download now, free

The future of the pharmacy doesn't wait. Get ready with the data.

Download Pharmacy Outlook Italia 2026 and discover where the market is heading, how your pharmacy's value will change and what to do today to stay competitive tomorrow.

Download the White Paper →